Yokota, S., Nozawa, T., Kanetaka, T., Yamazaki, K., Sato, T., Sakurai, N., & Kikuchi, M. (2013). PReS-FINAL-2166: Long-term safety and effectiveness of anti-interleukin-6 receptor monoclonal antibody, tocilizumab, in patients with systemic juvenile idiopathic arthritis in Japan. BioMed Central.
Citación estilo ChicagoYokota, S., T. Nozawa, T. Kanetaka, K. Yamazaki, T. Sato, N. Sakurai, and M. Kikuchi. PReS-FINAL-2166: Long-term Safety and Effectiveness of Anti-interleukin-6 Receptor Monoclonal Antibody, Tocilizumab, in Patients With Systemic Juvenile Idiopathic Arthritis in Japan. BioMed Central, 2013.
Cita MLAYokota, S., et al. PReS-FINAL-2166: Long-term Safety and Effectiveness of Anti-interleukin-6 Receptor Monoclonal Antibody, Tocilizumab, in Patients With Systemic Juvenile Idiopathic Arthritis in Japan. BioMed Central, 2013.